semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Parkinson Disease Dementia For all subjects: 1. Age 40 or older. 2. Able to abstain from caffeine and alcohol for 24 hours before each visit. 3. English is the first language. 4. Right handed For PD cohort: 1. Established diagnosis of PD. 2. History compatible with diagnosis of PD 3. Present with at least 3 of the following features: bradykinesia, resting tremor, cogwheel rigidity or postural reflex impairment 4. One of the 3 clinical features is either bradykinesia or resting tremor 5. Currently taking or history of taking dopaminergic therapy with symptomatic response. 6. Is able to give informed consent or, if there is evidence of cognitive decline, able to give assent and able to appoint a durable power of attorney (DPA) who can give informed consent  for all subjects Use of illegal drugs within the past 6 months More than 7 alcoholic drinks a week for females or 14 alcoholic drinks a week for males History of a neurologic disorder such as a brain tumor, stroke, central nervous system infection, multiple sclerosis, a movement disorder, epilepsy or a history of seizures, except PD for PD patients History of any head injury with loss of consciousness Pregnancy or positive pregnancy test before the research procedure due to the risks associated with MRI scans Inability to lie flat on the back for up to 2 hours Claustrophobia or a feeling of discomfort from being in small, enclosed spaces of enough severity to prevent MRI scanning Surgically or traumatically implanted metallic foreign bodies, such as pacemakers, implanted medical pumps, implanted hearing aids, metal plates in the skull or metal implants in the skull or eyes (other than dental fillings) that may be physically hazardous during an MRI, or might distort the images Ablative surgery or implanted electrodes and generator for deep brain stimulation
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Homozygous Familial Hypercholesterolemia Patients of any age and sex who meet clinical or genetic for hoFH as follows Cutaneous xanthomata before the age of ten years LDLC > 13 mmol/L before treatment or > 7.76 mmol/L despite treatment Phenotypic features in keeping with HeFH in both parents  Inability of patient, or, if less than 18, a parent, to sign informed consent
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Cirrhosis Hepatic Encephalopathy Ambulatory patient with cirrhosis Able to provide informed consent  History of alcohol abuse within six months Active gastrointestinal bleeding Unable to provide informed consent
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 1.75-999.0,  Parkinson Disease idiopathic Parkinson disease age >21 years able to provide written informed consent  diabetes mellitus, stroke, cardiac and renal diseases and cigarette smoking major psychiatric disorder or drug and/or alcohol abuse/dependence regular use of antioxidants, dietary supplements, traditional Chinese remedies, non-steroidal anti-inflammatory drugs or immunosuppressive drugs
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Movement Disorders Parkinson's Disease Patients will have a diagnosis of Parkinson Disease Age 18 or older Able to give informed consent Ability to comply by the schedule and routine of taking the at home tests with the QMAT system responsibly ability to perform the QMAT testing current or planned enrollment in 12-N-0137: A Phase 1 Open-label Dose Escalation Safety Study of Convection-Enhanced Delivery (CED) of Adeno-Associated Virus Encoding Glial Cell Line-Derived Neurotrophic Factor (AAV2-GDNF) in Subjects with Advanced Parkinson s Disease  Have more than 7 alcoholic drinks a week in the case of a woman or 14 alcoholic drinks a week in the case of a man Have had a brain tumor, a stroke, head trauma, epilepsy, or a history of seizures Have major depression or any major mental disorders (axis I disorders) Have other neurologic disorder than a movement disorder Have had a head injury where there was a loss of consciousness for more than a few seconds
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Parkinson's Disease Tremor Medication-refractory tremor and/or Parkinson's disease as defined by UK Brain Bank with either inadequate control of motor fluctuations or dyskinesia despite optimised medical therapy  Significant cognitive, psychiatric and medical co-morbidities Dementia with mini mental state examination score of less than 25/30 Limited life expectancy due to a co-morbid condition
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Polymorphism- Genetic Reward Mediating System Subjects will be eligible for this study if they are between 18 and 55 years of age are in good physical health speak English well enough to understand task instructions clearly  Subjects will not be eligible for this study if they have a major medical (e.g. heart disease), neurological (e.g. stroke) or psychiatric (e.g. bipolar disorder) illness have a vision and/or hearing problem that interferes with testing currently use any psychotropic medication, antidepressants, steroids or opiates currently use alcohol in excess of 14 drinks/week for males or 7 drinks/week for females have a lifetime history of or currently have alcohol or substance use or dependence (excluding nicotine) that requires independent, concurrent treatment intervention (such as, antabuse or opiate treatment). This does not self-help group treatment/intervention cannot understand the consent and procedures or cannot consent themselves to the study Smoke more than a half pack of cigarettes a day NIMH employees and staff and their immediate family members will be excluded from the study per NIMH policy. In addition to the above, additional apply for all MRI studies
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Essential Tremor Parkinson's Disease For Non-Caucasians Non-Caucasian male and female adult participants (greater than or equal to 18 years of age) with an initial diagnosis of suspected PD or ET who underwent DaTscan SPECT imaging to assist with the participant's final clinical diagnosis of PD or ET The participant had existing diagnostic-quality and interpretable DaTscan SPECT images of the brain. For Caucasians Caucasian male and female adult participants (greater than or equal to 18 years of age) with an initial diagnosis of suspected PD or ET who underwent DaTscan SPECT imaging to assist with the participant's final clinical diagnosis of PD or ET The participant had existing diagnostic-quality and interpretable DaTscan SPECT images of the brain The participant was matched by final clinical diagnosis, sex and age (±5 years) with a non-Caucasian participant  Known/suspected structural abnormalities of the brain (e.g., hydrocephalus; brain tumor; stroke; etc.) that could grossly distort the DaTscan images Participants whose race and ethnic information could not be determined from source document review
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 40.0-75.0,  Coronary Artery Disease Age between 40-75 years old 2. Male sex 3. History of known coronary artery disease (by either history of myocardial infarction, angiogram demonstrative >=50% stenosis in at least 1 major epicardial coronary artery, or a previous stress test that showed evidence of ischemia that has not been revealed to be a false positive test by angiography)  Unstable angina or myocardial infarction by history, ECG, and/or enzymatic within 1 month of enrollment. 2. Left ventricular dysfunction as defined by an left ventricular ejection fraction documented as < 45% within 1 year of enrollment by an echocardiogram, MRI, or nuclear imaging. 3. Uncontrolled hypertension with a blood pressure greater than 170/100 mmHg at the screening visit. 4. Known history of chronic renal insufficiency, liver dysfunction, or cancer besides non-melanoma skin carcinomas or localized prostate cancer requiring systemic treatment within five years of enrollment. 5. Known history of cognitive impairment or inability to follow study procedures 6. Patient with an implanted defibrillator or permanent pacemaker on with the potential participant is known to rely upon for greater than 50% of ventricular depolarizations. 7. Patients who received probiotics, prebiotics, and antibiotics in the last 12 weeks. 8. Patients with dosing changes of vasoactive medications and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the 6 weeks prior to enrollment
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 45.0-85.0,  Parkinson Disease Experimental subjects must meet the Brain Bank (Gibb & Lees, 1988) for idiopathic PD All participants must be between the ages of 45 and 85 have at least a sixth grade education fluent in English The investigators will obtain information about participant's Parkinson's disease history from medical records including age at onset current age gender handedness  Individuals will be excluded with other forms of Parkinsonism such as multiple systems atrophy Lewy body dementia progressive supranuclear palsy Other exclusionary will be co-existing dementia (as indicated by score on Montreal Cognitive Assessment of below 26) neurological disease other than idiopathic PD major depression any other psychiatric illness chronic medical and neurological diseases other than PD (e.g., cardiac failure, renal disease, hepatic failure, stroke, or severe sensory deficits such as deafness or blindness (corrected visual acuity less than 20/50)
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cerebral Vascular Accident (CVA) All patients, male or female, may be included if they meet the following patients with suspected ischemic CVA admitted in an acute stroke unit (thrombolysis unit) aged 18 and over MRI Scan undertaken under the current protocol which includes the following sequences: distribution, T2* (gradient echo), ARM, TOF and FLAIR after information given the consent form is signed by the patient .or for those unable to express their consent (in case of coma or severe neurological disorder) by a relative or next of kin. .the patient will be informed as soon as he has recovered his faculties in order to be able to express, if he wishes, his opposition to the pursuit of the research (sample destruction before tested) the patient must be registered with the Social Security  All patients with a contraindication to MRI Scan Pacemaker Implanted cardiac defibrillator Implanted Neuro-stimulator Cochlear Implants Implanted Insulin pump Other implanted electronic medical device Vascular intracerebral Clip Cardiac Valve Other metallic implant
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Adhesive Capsulitis of the Shoulder patients must be diagnosed as having idiopathic adhesive capsulitis in the 'frozen' or 'thawing' phase of disease and have tried and failed at least 3 months of nonoperative therapy. OR patient with adhesive capsulitis who presents already in the 'frozen' or 'thawing' phase who demands a quicker return to function and will not try 3 months of nonoperative therapy first Age 18 or older  pregnancy previously operated shoulder (same side) other documented source of shoulder pain and stiffness (same side) rotator cuff tear (same side) glenohumeral osteoarthritis (same side) calcific tendonitis (same side) impingement (same side) osteonecrosis neoplasm cervical radiculopathy
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Idiopathic Parkinson's Disease Patients with IPD who have been on a stable dose of anti-parkinsonian medication for at least one month Hoehn & Yahr scale I-IV More than one point in two or more items (tremor, rigidity, postural instability, and bradykinesia) in the UPDRS Part III, etc  Severe psychiatric or organic brain disorders other than PD, previous or current Secondary Parkinsonism due to cerebrovascular disease, tumor, infection, etc Atypical Parkinsonian or Parkinson plus syndrome
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 40.0-85.0,  Parkinson's Disease A diagnosis of idiopathic Parkinson's Disease (PD) (UK, PD Brain Bank Criteria) A Hoehn and Yahr stage of 2 Exhibiting Freezing of Gait or another gait abnormality in the ON state An ability to mobilise independently with or without a walker or walking cane for the purpose of research when in the 'ON' state  A serious cognitive impairment (MMSE<24) Pregnant or currently involved in another clinical trial Pacemakers On opioid or neuropathic pain medication